HopeStage
Back to all studies
CompletedNCT00435370

Tropisetron added to risperidone for cognitive and perceptual difficulties in schizophrenia

About this titleRead the official source — NCT00435370
Medication studyAges 18–64United States + China
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 64 years.

Listed locations
Houston and 1 more locationSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2006
Recruitment status
Completed
Enrollment listed in the registry
179
Sponsor
Baylor College of Medicine
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, China
Age range
From 18 Years to 64 Years
Official registry ID
NCT00435370
Official title
Show the full official title

Tropisetron With Risperidone for Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Houston, United States · Beijing, China

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Baylor College of Medicine, a university.

Did this study involve medication?

Yes. The study involved medication, including Tropisetron, Placebo and Risperidone.

Who was this study for?

Listed age limits: 18 years to 64 years.

Want to explore more studies?

Explore studies